Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-02-20
1999-09-07
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514457, 514460, 514851, A01N 4316, A61K 3135
Patent
active
059488140
ABSTRACT:
A method of treating cystic fibrosis by generating cystic fibrosis transmembrane conductance regulator (CFTR) function in cells containing mutant CFTR and the therapeutic composition for treatment are described. The method of treatment comprising administering an effective amount of genistein, or genistein analogues and derivatives, to a person afflicted with cystic fibrosis.
REFERENCES:
Akiyama et al., Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262: 5592-5595, 1987.
Baukrowitz et al., Coupling of CFTR C1.sup.-- channel gating to an ATP hydrolysis cycle. Neuron 12: 473-482, 1994.
Berger et al., Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. J. Clin. Invest. 88: 1422-1431, 1991.
Bradbury et al., Regulation of plasma membrane recycling by CFTR, Science 258: 530-582, 1992.
Carson et al., The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. J. Biol Chem. 270: 1711-1717, 1995.
Cheng et al., Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834, 1990.
Collins et al., Cystic Fibrosis: molecular biology and therapeutic implications, Science 256: 774-779, 1992.
Dalemans et al., Altered chloride ion channel kinetics associated with the .increment.F508 cystic fibrosis mutation. Nature 354: 526-528, 1991.
Denning et al., Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764, 1992.
Drumm et al., Chloride conductance expressed by .increment.F508 and other mutant CFTRs in Xenopus cocytes. Science 254: 1797-1799, 1991.
Frizzell, et al., Altered Regulation of Airway Epithelial Cell Chloride Channels in Cystic Fibrosis. Science 233: 558, 1986.
Gadsby et al. The CFTR chloride channel of mammalian heart. Annu. Rev. Physiol. 57: 387-416, 1995.
Gunderson et al., Conformational states of CFTR associated with channel gating; the role of ATP binding and hydrolysis. Cell 82: 231-239, 1995.
Gunderson et al., Effects of pyrophosphate and nucleotide analogs suggest a role for ATP hydrolysis in cystic fibrosis transmembrane regulator channel gating. J. Biol. Chem. 269: 19349-19353, 194.
Haws et al., CFTR in Calu-3 human airway cells; channel properties and role in cAMP-activated C1.sup.-- conductance. Am. J. Physiol. 266 (Lung Cell, Mol. Physiol 10): L502-L512, 1994.
Haws et al., .increment.F508-CFTR channels: kinetics, activation by forskolin, and potentition by xanthines. Am. J. Physiol. 270 (Cell Physiol. 39): C1544-C1555, 1996.
Huang et al., Genistein inhibits protein histidine kinase. J. Biol. Chem. 267: 15511-15515, 1992.
Hunter, Protein kinases and phosphatases: the Yin and Yang of protein phosporylation and signaling. Cell 80: 225-236, 1995.
Hwang et al., Regulation of the gating of cystic fibrosis transmembrane conductance regulator C1 channels by phosphorylation and ATP hydrolysis. Proc. Natl. Acad. Sci USA 91: 4698:4702, 1994.
Illek et al, Alternate stimulation of apical CFTR by genistein in epithelia. Am. J. Physiol. 270 (Cell Physiol. 39): C265-C275, 1996.
Illek et al., Cyclic AMP-independent activation of CFTR C1 channels by the tyrosine kinase inhibitor genistein. Am. J. Physiol. 258 (Cell Physiol. 37): C886-C893, 1995.
Lehrich et al., Tyrosine phosphorylation is a novel pathway for regulation of chloride secretion in shark rectal gland. Am. J. Physiol. 269 (Renal Fluid Electrolyte Physiol. 38): F594-F600, 1995.
Li et al., The cystic fibrosis mutation (.increment.F508) does not influence the chloride channel activity of CFTR Nat. Genet. 8: 311-316, 1993.
Markovits et al., Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49: 5111-5117, 1989.
Messina et al., Soy intake and cancer risk: a review of in vitro and in vivo data. Nutr. Cancer 21: 113-131, 1994.
Ramsey, Management of pulmonary disease in patients with cystic fibrosis. NEJM. 335: 179-188, 1996.
Reenstra et al., CFTF chloride channel activation by genistein: the role of serine/threonine protein phosphatases. Am. J. Physiol. 271 (Cell Physiol. 40): C650-C657, 1996.
Riordan et al., Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073, 1989.
Schoumacher et al., Phosphorylation fails to activate chloride channels from cystic fibrosis airway cells. Nature 330: 752, 1987.
Sigworth et al., The variance of sodium current fluctuations at the node of Ranvier. J. Physiol. (Lond.) 307: 97-129, 1980.
Smit, et al., Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator. Proc. Natl. Acad. Sci USA 90: 9963-9967, 1993.
Suganuma et al., Calyculin A, an inhibitor of protein phosphotases, a potent tumor promoter on CD-1 mouse skin. Cancer Res. 50: 3521-3525, 1990.
Welsh et al., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73: 1251-1254, 1993.
Yang et al., Modulation of CFTR chloride channels by calyculin and genistein. Am. J. Physiol. 272 (Cell Physiol. 41): C142-C155, 1997.
Hutchins, et al., Vegetables, fruits and legumes: effects or urinary isoflavonoid phytoestrogen and lignan excretion. J. Am. Diet. Assoc. 95:769-774, 1995.
Kavanagh, et al., Drug Disposition in Cystic Fibrosis. Cystic Fibrosis, edited by Pamela B. Davis, Marcel Dekker, Inc., New York, pp. 91-136, 1993.
Kiser, et al., Two-hybrid analysis of CFTR domain interactions (Abstract). Ped. Pulman. 513:213, 1998.
Li, et al., Nature 331:358, 1988.
Widdicombe, et al., Trends in Biological Science 16:474-477, 1991.
Clarke Lane L.
Cohn Leah A.
Hwang Tzyh-Chang
Konig Peter
Price Elmer M.
Krass Frederick
The Curators of the University of Missouri
LandOfFree
Genistein for the treatment of cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genistein for the treatment of cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genistein for the treatment of cystic fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804963